Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaMarkus Hansson, Peter Gimsing, Ashraf Badros, et al.
British Journal of Haematology|March 29, 2002
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestationsAthanasios B-T Fassas, Firas Muwalla, Tanya Berryman, et al.
Future Oncology (London, England)|February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
Blood Cancer Journal|October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analysesLaahn Foster, Larry D Anderson, Alfred Chung, et al.
British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.
Pageof 7